Cellectar Biosciences, Inc. (NASDAQ:CLRB) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Posted by Amy Steele on Oct 2nd, 2026

Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) has earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $11.00.

CLRB has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Cellectar Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Friday, July 17th. Finally, Brookline Capital Markets upgraded shares of Cellectar Biosciences to a “strong-buy” rating in a research report on Sunday, July 12th.

View Our Latest Stock Report on CLRB

Cellectar Biosciences Price Performance

NASDAQ:CLRB opened at $1.87 on Friday. Cellectar Biosciences has a one year low of $1.80 and a one year high of $6.52. The company has a market cap of $17.67 million, a P/E ratio of -0.49 and a beta of 0.58. The firm’s fifty day moving average price is $2.40 and its two-hundred day moving average price is $2.66.

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). As a group, equities research analysts expect that Cellectar Biosciences will post -2.39 earnings per share for the current year.

Cellectar Biosciences Company Profile

(Get Free Report)

Cellectar Biosciences, Inc (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiopharmaceuticals and drug-delivery technologies for the treatment of cancer. The company’s approach is based on phospholipid ether (PLE) compounds, which are designed to selectively accumulate in cancer cells and other tumor-associated tissues.

Cellectar’s lead product candidate is iopofosine I 131, also known as CLR 131, a targeted radiotherapeutic being developed for hematologic malignancies, including certain forms of B-cell lymphoma and multiple myeloma.